Answers are grounded in this paper and cite their sources.
Primary vaginal cancer is rare, and its definitive nonsurgical treatment is supported mainly by observational cohorts, technique-specific series, and evidence extrapolated from cervical cancer.Although contemporary reviews and guidelines describe increasingly sophisticated radiotherapy, an unresolved question is how to translate associative treatment signals into decisions that remain feasible, timely, and acceptable to patients.We undertook a purposive critical narrative synthesis of primary vaginal cancer radiotherapy literature, drawing on author-recorded PubMed searches, citation tracking, landmark historical cohorts, and contemporary guidelines.We examined concurrent chemoradiotherapy, brachytherapy access and technique, cumulative dose, treatment completion, and late morbidity while identifying cohort overlap and threats to causal interpretation.In a National Cancer Database cohort, median overall survival was 56.2 months with concurrent chemoradiation versus 41.2 months with radiation alone.In a population registry analysis of 2,517 patients, brachytherapy exposure was associated with lower mortality after propensity matching (hazard ratio 0.77, 95% confidence interval 0.68-0.86).The 148-patient Retrospective International Image-Based Adaptive Brachytherapy for Vaginal Cancer (retroEMBRAVE) cohort reported five-year local control of 83%, alongside clinically important severe pelvic morbidity.These observations support multidisciplinary consideration of brachytherapy but cannot establish treatment-specific causal effects.We propose an evidence-to-delivery framework linking disease phenotype, technically deliverable radiotherapy, treatment continuity, and survivorship.Its accompanying research matrix specifies the confounders, outcomes, and prospective data required to evaluate chemotherapy, brachytherapy, treatment duration, and dose-toxicity relationships.The framework is an unvalidated organising tool, not a predictive score or new clinical guideline.
No takes yet. Share an insight, caveat, or question.
Fenech et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: